12113Background: Targeting immune checkpoints has led to clinical benefit across a variety of tumor types, and employing combinations has enhanced response rates even further. We hypothesize that p... Click to show full abstract
12113Background: Targeting immune checkpoints has led to clinical benefit across a variety of tumor types, and employing combinations has enhanced response rates even further. We hypothesize that p...
Click one of the above tabs to view related content.